- Home
- ELWS vs SNSE Comparison
ELWS vs SNSE Comparison
Compare ELWS & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELWS
- SNSE
- Stock Information
- Founded
- ELWS 2018
- SNSE 2005
- Country
- ELWS Japan
- SNSE United States
- Employees
- ELWS N/A
- SNSE N/A
- Industry
- ELWS
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- ELWS
- SNSE Health Care
- Exchange
- ELWS Nasdaq
- SNSE Nasdaq
- Market Cap
- ELWS 12.9M
- SNSE 14.5M
- IPO Year
- ELWS 2023
- SNSE 2021
- Fundamental
- Price
- ELWS $4.23
- SNSE $9.11
- Analyst Decision
- ELWS
- SNSE Strong Buy
- Analyst Count
- ELWS 0
- SNSE 4
- Target Price
- ELWS N/A
- SNSE $72.50
- AVG Volume (30 Days)
- ELWS 1.7M
- SNSE 63.9K
- Earning Date
- ELWS 09-30-2025
- SNSE 11-13-2025
- Dividend Yield
- ELWS N/A
- SNSE N/A
- EPS Growth
- ELWS N/A
- SNSE N/A
- EPS
- ELWS N/A
- SNSE N/A
- Revenue
- ELWS $3,083,071.00
- SNSE N/A
- Revenue This Year
- ELWS N/A
- SNSE N/A
- Revenue Next Year
- ELWS N/A
- SNSE N/A
- P/E Ratio
- ELWS N/A
- SNSE N/A
- Revenue Growth
- ELWS 145.52
- SNSE N/A
- 52 Week Low
- ELWS $1.64
- SNSE $5.00
- 52 Week High
- ELWS $10.50
- SNSE $18.35
- Technical
- Relative Strength Index (RSI)
- ELWS 57.75
- SNSE 43.94
- Support Level
- ELWS $4.07
- SNSE $9.07
- Resistance Level
- ELWS $4.75
- SNSE $11.86
- Average True Range (ATR)
- ELWS 0.89
- SNSE 1.88
- MACD
- ELWS 0.01
- SNSE -0.46
- Stochastic Oscillator
- ELWS 24.01
- SNSE 0.48
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).